Alix-Doucet, Anne Sophie
Vinatier, Constant
Fin, Loïc
Léna, Hervé
Rangé, Hélène
Locher, Clara
Naudet, Florian
Article History
Received: 20 December 2023
Accepted: 15 April 2024
First Online: 22 April 2024
Declarations
:
: Not applicable.
: Not applicable.
: All authors, except CV are employed by CHU Rennes.The authors declare the following other interests: CV received funding as part of the OSIRIS project (Open Science to Increase Reproducibility in Science); the OSIRIS (Open Science to Increase Reproducibility in Science) project has received funding from the EU (grant agreement No. 101094725). HL received funding from Roche, Astrazeneca, MSD, Novartis, Takeda, BMS, ROCHE, MSD, Pfizer, Lilly, Amgen for consultancy. From BMS TAKEDA PFIZER, for lectures fee and Support for attending meetings and/or travel from Sanofi, Pfizer, Takeda, Roche, Amgen. HR reports lecture fee or consultancy from Biocodex, Colgate-Palmolive, and Procter & Gamble. CL is involved in the doctoral network MSCA-DN SHARE-CTD (HORIZON-MSCA-2022-DN-01 101120360), funded by the EU, with additional contributions from Bayer, Smart Data Analysis and Statistics, SciCrunch, and ECRIN-ERIC. UM is the coordinator of MSCA-DN SHARE-CTD. FN received funding from the French National Research Agency (ANR-17-CE36-0010), the French Ministries of Health and Research. FN is a work package leader in the OSIRIS project; FN is also a WP leader in MSCA-DN SHARE-CTD. LF and ASAS no conflicts of interests.